Increased blood flow and vascular leakage of proteins preferentially affect tissues that are sites of diabetic complications in humans and animals. These vascular changes in diabetic rats are largely prevented by aminoguanidine. Glucose-induced vascular changes in nondiabetic rats are also prevented by aminoguanidine and by A^-monomethyl-L-arginine (NMMA), an established inhibitor of nitric oxide (NO) formation from L-arginine. Aminoguanidine and NMMA are equipotent inhibitors of interleukin-1 p-induced 1) nitrite formation (an oxidation product of NO) and cGMP accumulation by the rat p-cell insulinoma cell line RINm5F, and 2) inhibition of glucose-stimulated insulin secretion and formation of iron-nitrosyl complexes by islets of Langerhans. In contrast, NMMA is ~40 times more potent than aminoguanidine in elevating blood pressure in nondiabetic rats. These results demonstrate that aminoguanidine inhibits NO production and suggest a role for NO in the pathogenesis of diabetic vascular complications. Diabetes 41:552-56, 1992 N itric oxide synthase catalyzes the mixed functional oxidation of a guanidino nitrogen atom of L-arginine to yield L-citrulline and NO-(1,2). The constitutive isoform of NO-synthase is Ca 2+ dependent and produces small amounts of NO-that activate guanylate cyclase, resulting in the formation of cGMP, which mediates endothelium-dependent relaxation (2) and neural transmission (3). NO-is produced in much larger amounts by the cytokine-and endotoxininducible isoform of NO-synthase, which is Ca 2+ inde-
pendent and appears to mediate the cytotoxic actions of macrophages on target cells (4) . Because NO-is a potent vasodilator and increases blood flow, and because endothelium-dependent vasoactive agents (e.g., histamine and bradykinin) increase both blood flow and vascular permeability, NO-is a candidate for mediating increases in blood flow and vascular permeability induced by diabetes (5) .
Interleukin-1 (IL-1) induces NO-synthase in pancreatic islets, and increased production of NO-has been proposed to mediate IL-1 's inhibitory affects on islet function (6, 7) . Formation of NO-by islets has been confirmed by the inhibition of an IL-1-induced, electron paramagnetic resonance (EPR)-detectable iron-nitrosyl complex by A^-monomethyl-L-arginine (NMMA) (7) . In addition, a protein synthesis inhibitor, cycloheximide, blocks IL-1-induced nitrite formation, cGMP accumulation, and ironnitrosyl complex formation by islets, thus establishing that IL-1 induces the cytokine-inducible isoform of NOsynthase in pancreatic islets (7; unpublished observations).
The pathogenesis of diabetic complications has been linked to imbalances in sorbitol, myo-inositol, 1,2-diacylsn-glycerol metabolism, and to nonenzymatic glycosylation of cellular and extracellular constituents (5) . The glycosylation link is supported by evidence that aminoguanidine, a nucleophilic hydrazine compound, interferes with the formation of these glycosylation products and also attenuates the development of several diabetesinduced vascular (5, 8, 9) , neural (10) , and collagen changes (11) . Bucala et al. (12) recently reported that quenching of NO-in vitro by glycosylated albumin is attenuated by aminoguanidine (present during exposure of albumin to glycosylating agents) and suggested that glycosylation products may impair endothelium-dependent relaxation by attenuating NO-activity.
We (J.R.W.) recognized that aminoguanidine is structurally similar to L-arginine in that these compounds contain two chemically equivalent guanidino nitrogen 552 DIABETES, VOL. 41, APRIL 1992 groups (see structures below) and to L-arginine analogues that competitively inhibit NO-synthase (e.g., A^-monomethyl-L-arginine). For this reason, we investigated the possibility that aminoguanidine might modulate isolated by centrifugation and frozen at -70°C. EPR spectroscopy was performed at 77 K on the islets with a Varian E-109 spectrometer equipped with a 9.5 GHz microwave bridge as described previously (7 lcGMP kits were obtained from Du Pont-NEN (Boston, MA). Nitrite determination. RINm5F cells, obtained from the Washington University Tissue Culture Support Center, were removed from growth flasks (55-80 million cells/ flask) by 0.05% trypsin/0.02% EDTA treatment and aliquoted into 1-ml petri dishes (1-2 million RINm5F cells/ condition). Cells were incubated for 18 h under an atmosphere of 95% air/5% CO 2 in 1 ml complete CMRL-1066 tissue culture media containing 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 |xg/ml streptomycin or complete CMRL-1066 supplemented with 5 U/ml IL-ip, aminoguanidine, NMMA, or both IL-ip and aminoguanidine or IL-1p and NMMA. After incubation, the supernatant was removed, and nitrite was determined on 100-|xl aliquots as described previously (7) . Measurement of cGMP levels. cGMP accumulation was determined on 8 million RINm5F cells incubated for 18 h in complete CMRL-1066 or complete CMRL-1066 as described above, followed by an additional 3-h incubation in fresh complete CMRL-1066 containing 1 mM isobutyl-methylxanthine plus or minus aminoguanidine or NMMA. RINm5F cells were isolated by centrifugation, and cGMP was measured by radioimmunoassay. Insulin secretion by isolated islets. For insulin secretion studies, islets were isolated by collagenase digestion from male Sprague-Dawley rats (250-300 g) as described previously (13) . The isolated islets (120/ml) were pretreated in complete CMRL-1066 or complete CMRL-1066 supplemented as described above for 18 h at 37°C under an atmosphere of 95% air/5% CO 2 , and insulin secretion was measured as described previously (7). EPR spectroscopy. Isolated islets (2400) were cultured in 3 ml complete CMRL-1066 or complete CMRL-1066 supplemented as described above for 18 h at 37°C under an atmosphere of 95% air/5% CO 2 . The islets were
Mean arterial blood pressure (MAP) measurements.
Nondiabetic male Sprague-Dawley rats were anesthetized with 100 mg/kg body wt Inactin), the left femoral vein (for tracer injection) and right iliac artery (for monitoring blood pressure) were cannulated with PE tubing filled with heparinized saline, and the trachea was cannulated and connected to a small-rodent respirator for continuous ventilatory support. After stabilization of arterial pressure, increasing amounts of aminoguanidine or NMMA (|xmoles/kg body wt) in a constant volume were injected intravenously in separate rats, and the peak pressure increase was recorded. Measurement of vascular albumin permeation and blood flow. Glucose-induced increases in vascular albumin permeation were assessed in skin chamber granulation tissue in nondiabetic rats (14) . Beginning 7 days after inserting the chambers, 1.5 ml HEPES buffer, pH 7.4 (25 mM HEPES, 137 mM NaCI, 4.2 mM KCI, 3 mM Na 2 HPO 4 , 0.3 mM L-arginine, 100 ng/ml penicillin G, 10 ixg/ml gentamicin), containing 5 mM glucose or 30 mM glucose plus or minus 1 mM aminoguanidine or 1 mM NMMA was added to each chamber (r? = 4 for each experimental condition) twice daily for 7 days. Within 1 h of the last treatment, 131 l-labeled bovine serum albumin (BSA) clearance was assessed as previously described (14) .
Diabetes-induced increases in vascular albumin permeation and blood flow were assessed in four groups of male Sprague-Dawley rats (-250 g) as follows: group 1, nondiabetic controls (n = 8); group 2, controls treated with aminoguanidine (n = 8); group 3, untreated diabetic rats (n = 11); and group 4, diabetic rats treated with aminoguanidine (n = 9). Diabetes was induced by injection of 55 mg/kg body wt i.v. streptozocin, at which time rats in groups 2 and 4 were started on daily injections of 50 mg/kg body wt s.c. aminoguanidine. Vascular permeability ( 131 I-BSA clearance; 15) was assessed after 5 wk of diabetes. Regional blood flow (n = 7/group) was measured after 4 mo of diabetes with 15-jx,m 85 Sr microspheres as described previously (15) .
RESULTS
The effects of aminoguanidine on IL-1p-induced formation of nitrite and cGMP by RINm5F cells were initially examined. C isolated islets (120/ml) were pretreated in complete CMRL-1066 or complete CMRL-1066 containing 5 U/ml IL-10 ± 0.5 mM aminoguanidine or IL-ip and aminoguanidine for 18 h. After pretreatment, glucose-stimulated insulin secretion was measured as described in METHODS.
and NMMA inhibit IL-1p-induced nitrite production in a dose-dependent fashion with half maximal inhibition at -1 0 ixM. Figure 1B demonstrates that IL-1p-induced accumulation of cGMP (a sensitive index of NO-production) in RINm5F cells was completely blocked by aminoguanidine and by NMMA, providing further evidence that aminoguanidine inhibits NO-production. The complete prevention by aminoguanidine of IL-ip-induced
FIG. 2. Effects of aminoguanidine (AG) on interleukin-1 p (IL-1 p)-induced iron-nitrosyl complex formation by isolated islets.
Islets (2400) were cultured in complete CMRL-1066 or complete CMRL-1066 containing 5 U/ml IL-ip ± 0.5 mM aminoguanidine for 18 h at 37°C, 95% air/5% CO 2 . The Islets were frozen for electron paramagnetic resonance spectroscopy (7), and nitrite was determined on the supernatant. Data are from 3 individual experiments. The IL-1 p-induced iron-nitrosyl g = 2.04 complex and the delocalized electron g = 2.0023 features (found in all cells) are Indicated by arrows.
inhibition of glucose-stimulated insulin secretion is shown in Fig. 1C . Although aminoguanidine appears to slightly potentiate insulin secretion by islets in the absence of IL-13 (as has also been observed for NMMA), this effect is not statistically significant (P > 0.075).
To confirm that aminoguanidine inhibits IL-1p-induced NO-production, the effect of aminoguanidine on IL-1 ( Binduced formation of a g = 2.04 EPR-detectable ironnitrosyl feature in islets was investigated. Figure 2 demonstrates that 0.5 mM aminoguanidine completely prevents the formation of this IL-13-induced iron-nitrosyl feature and the concurrent formation of nitrite by the same islets used for EPR spectroscopy. The formation of this feature has been used previously to confirm the formation of NO-in islets treated with IL-1 p (7), in activated macrophages (16) , and in target cells recognized by activated macrophages (17) . These results confirm that aminoguanidine prevents IL-1-induced formation of NO-and suggest that it is a potent inhibitor of the cytokine-inducible isoform of NO-synthase.
Effects of aminoguanidine on constitutive (vascular) NO-synthase production were assessed by monitoring MAP changes after injection of aminoguanidine in anesthetized nondiabetic rats (Fig. 3) . Both compounds increase MAP in a dose-dependent fashion, although NMMA is ~40-fold more potent (P < 0.004) than aminoguanidine. The difference in sensitivity does not ap- pear to be due to inhibitory effects of aminoguanidine on diamine oxidase activity (18) , because pretreatment with diphenhydramine (an H-, receptor blocker) has no effect on aminoguanidine-induced increases in MAP (data not shown). These observations suggest that although aminoguanidine and NMMA are equipotent inhibitors of cytokine-induced NO-production in vitro, aminoguanidine is much less potent than NMMA as an inhibitor of constitutive NO-production in vivo.
To assess the putative role of NO-in mediating glucose-induced vascular dysfunction, the effects of 1 mM aminoguanidine and of 1 mM NMMA on 30 mM glucoseinduced increases in vascular clearance of 131 l-labeled albumin were examined in a skin chamber granulationtissue model in nondiabetic rats (14) . As shown in Fig.  4 /A, 30 mM glucose causes an approximately twofold (P< 0.005) increase in 131 l-albumin clearance, which is completely prevented by coadministration of aminoguanidine or NMMA. Similarly, in rats with streptozocin-induced diabetes of 5-wk duration, daily injections of aminoguanidine prevent the two-to four-fold increases in 131 l-albumin clearance in ocular tissues (P< 0.001) including the retina (Fig. 48) , sciatic nerve (8) , and aorta (unpublished observations). Likewise, in rats with diabetes of 4-mo duration, aminoguanidine prevents blood flow increases (P < 0.001) in the retina (Fig. AC) . In these studies, aminoguanidine has no effect on blood pressure or on tissue sorbitol levels (data not shown).
DISCUSSION
These observations demonstrate that aminoguanidine is equipotent to NMMA as an inhibitor of cytokine-induced NO-formation in RINm5F cells and in isolated islets. In contrast, the effects of aminoguanidine on MAP suggest that it is only ~1/40th as effective as NMMA as an inhibitor of constitutive NO-production. The likelihood that diabetes-induced vascular dysfunction is mediated and/or modulated by NO-is supported by evidence that 1) the effects of aminoguanidine on blood flow and vascular albumin permeation in diabetic rats were restricted to tissues manifesting vascular dysfunction and 2} in nondiabetic rats, aminoguanidine had no effect on vascular function in the same tissues in which it normalized dysfunction in diabetic rats.
The findings that blood pressure was not increased in diabetic rats (data not shown) and that vascular dysfunction preferentially affects selected tissues, i.e., eyes, peripheral nerve, aorta, and kidneys, are consistent with 1) the well-known autocrine and paracrine effects of NO-(2), and 2) the hypothesis that diabetes induces a selective, relative or absolute, increase in NO-production in tissues that are sites of complications and vascular dysfunction. The likelihood that normalization of vascular function by aminoguanidine in our studies primarily reflects inhibition of NO-production (versus alternative mechanisms, see below) is suggested by 1) the brief duration (48 h cumulative) of elevated glucose levels in the granulation tissue model (14) , 2) the failure of aminoguanidine to decrease tissue sorbitol levels, 3) the prevention by aminoguanidine of 1 mM sorbitol-induced vascular permeability in granulation tissue in nondiabetic rats (22) , and 4) evidence that topical application of nitroglycerin (which spontaneously releases NO-) to granulation tissue mimics the effects of elevated glucose levels on vascular function (unpublished observations).
However, these observations and conclusions are discordant with the view that vascular NO-production is decreased by diabetes. The latter view is based primarily on reports of impaired endothelium-dependent relaxation in vitro of aortic rings from diabetic animals (19, 20) . In most of these studies, however, aortic contractile function has been assessed in media lacking L-arginine as substrate for NO-production and/or in media in which the glucose levels differed substantially from those of the donor animal. The demonstration that aminoguanidine is a potent inhibitor of NO-production, together with evidence that it also inhibits aldose reductase (21) and diamine oxidase (18) and formation of advanced glycosylation end products (11) attests to the potential of aminoguanidine to modulate glucose and diabetes-induced complications by multiple mechanisms.
These observations suggest that aminoguanidine may have therapeutic potential as an inhibitor of NO-production with much less risk of causing hypertension than L-arginine analogue inhibitors of nitric oxide synthase such as NMMA.
